CHEBI:6402 - leflunomide

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name leflunomide
ChEBI ID CHEBI:6402
Definition A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C12H9F3N2O2
Net Charge 0
Average Mass 270.20730
Monoisotopic Mass 270.062
InChI InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChIKey VHOGYURTWQBHIL-UHFFFAOYSA-N
SMILES Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F
Roles Classification
Biological Role(s): tyrosine kinase inhibitor
Any protein kinase inhibitor that interferes with the action of tyrosine kinase.
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor
An EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor that interferes with the action of dihydroorotate oxidase (fumarate), EC 1.3.98.1 (formerly EC 1.3.3.1).
hepatotoxic agent
A role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
pyrimidine synthesis inhibitor
A pathway inhibitor that inhibits the synthesis of pyrimidine.
immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor
Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
Application(s): non-steroidal anti-inflammatory drug
An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
antiparasitic agent
A substance used to treat or prevent parasitic infections.
prodrug
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing leflunomide (CHEBI:6402) has role antineoplastic agent (CHEBI:35610)
leflunomide (CHEBI:6402) has role antiparasitic agent (CHEBI:35442)
leflunomide (CHEBI:6402) has role EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor (CHEBI:68542)
leflunomide (CHEBI:6402) has role EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor (CHEBI:37153)
leflunomide (CHEBI:6402) has role hepatotoxic agent (CHEBI:50908)
leflunomide (CHEBI:6402) has role immunosuppressive agent (CHEBI:35705)
leflunomide (CHEBI:6402) has role non-steroidal anti-inflammatory drug (CHEBI:35475)
leflunomide (CHEBI:6402) has role prodrug (CHEBI:50266)
leflunomide (CHEBI:6402) has role pyrimidine synthesis inhibitor (CHEBI:68543)
leflunomide (CHEBI:6402) has role tyrosine kinase inhibitor (CHEBI:38637)
leflunomide (CHEBI:6402) is a (trifluoromethyl)benzenes (CHEBI:83565)
leflunomide (CHEBI:6402) is a isoxazoles (CHEBI:55373)
leflunomide (CHEBI:6402) is a monocarboxylic acid amide (CHEBI:29347)
IUPAC Name
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
INNs Sources
leflunomida WHO MedNet
leflunomide WHO MedNet
léflunomide WHO MedNet
leflunomidum WHO MedNet
Synonyms Sources
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide ChemIDplus
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide ChEBI
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide ChemIDplus
Leflunomide KEGG COMPOUND
Brand Name Source
Arava KEGG DRUG
Manual Xrefs Databases
1552 DrugCentral
C07905 KEGG COMPOUND
D00749 KEGG DRUG
DB01097 DrugBank
DE2854439 Patent
HMDB0015229 HMDB
Leflunomide Wikipedia
LSM-3771 LINCS
US4284786 Patent
View more database links
Registry Numbers Types Sources
4323174 Beilstein Registry Number Beilstein
4323174 Reaxys Registry Number Reaxys
75706-12-6 CAS Registry Number KEGG COMPOUND
75706-12-6 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
10515382 PubMed citation Europe PMC
10702725 PubMed citation Europe PMC
10890256 PubMed citation Europe PMC
11043056 PubMed citation Europe PMC
11053058 PubMed citation Europe PMC
11067959 PubMed citation Europe PMC
11271257 PubMed citation Europe PMC
11333342 PubMed citation Europe PMC
11340750 PubMed citation Europe PMC
11391470 PubMed citation Europe PMC
11475244 PubMed citation Europe PMC
11522581 PubMed citation Europe PMC
11707749 PubMed citation Europe PMC
11718154 PubMed citation Europe PMC
11876141 PubMed citation Europe PMC
11884931 PubMed citation Europe PMC
11994686 PubMed citation Europe PMC
12017890 PubMed citation Europe PMC
12074690 PubMed citation Europe PMC
12833393 PubMed citation Europe PMC
14622739 PubMed citation Europe PMC
15030575 PubMed citation Europe PMC
15127968 PubMed citation Europe PMC
15127974 PubMed citation Europe PMC
15188371 PubMed citation Europe PMC
15214907 PubMed citation Europe PMC
15385935 PubMed citation Europe PMC
15489872 PubMed citation Europe PMC
15537652 PubMed citation Europe PMC
15652966 PubMed citation Europe PMC
15665760 PubMed citation Europe PMC
15789891 PubMed citation Europe PMC
15899055 PubMed citation Europe PMC
15934905 PubMed citation Europe PMC
16106593 PubMed citation Europe PMC
16142756 PubMed citation Europe PMC
16202258 PubMed citation Europe PMC
16284916 PubMed citation Europe PMC
16638062 PubMed citation Europe PMC
16638420 PubMed citation Europe PMC
16645972 PubMed citation Europe PMC
16688677 PubMed citation Europe PMC
16769661 PubMed citation Europe PMC
16778342 PubMed citation Europe PMC
17366662 PubMed citation Europe PMC
17604599 PubMed citation Europe PMC
17646975 PubMed citation Europe PMC
17854740 PubMed citation Europe PMC
18034546 PubMed citation Europe PMC
18173611 PubMed citation Europe PMC
18413415 PubMed citation Europe PMC
18496682 PubMed citation Europe PMC
18663553 PubMed citation Europe PMC
18688040 PubMed citation Europe PMC
19169882 PubMed citation Europe PMC
19190124 PubMed citation Europe PMC
19344337 PubMed citation Europe PMC
19581389 PubMed citation Europe PMC
19715969 PubMed citation Europe PMC
19751817 PubMed citation Europe PMC
19770782 PubMed citation Europe PMC
7496341 PubMed citation Europe PMC
7676489 PubMed citation Europe PMC
8610393 PubMed citation Europe PMC
9075844 PubMed citation Europe PMC
9123314 PubMed citation Europe PMC
9625011 PubMed citation Europe PMC
9777697 PubMed citation Europe PMC
Last Modified
22 February 2017